Track topics on Twitter Track topics that are important to you
NEW YORK, June 05, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against TrueCar, Inc. (“TrueCar” or the “Company”) (Nasdaq:TRUE). The class action, filed in United States District Court for the Central District of California, is on behalf of a class consisting of all persons or entities who purchased TrueCar securities between May 16, 2014 and May 20, 2015 inclusive (the “Class Period”). Wolf Haldenstein encourages all shareholders who suffered losses on securities purchased within the Class Period to contact us immediately at email@example.com or (800) 575-0735.
TrueCar’s business model is an Internet-based information, technology, and communication services company. The Company operates its platform on the TrueCar Website and TrueCar mobile applications. It also customizes and operates its platform for its group marketing partners, including financial institutions, membership-based organizations, and employee buying programs for large enterprises.
The Complaint alleges that defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business operations and performance. Specifically, during the Class Period, the Complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (i) TrueCar’s business practices violated unfair competition and deceptive trade practice laws; (ii) TrueCar acts as a dealer and broker in car sales transactions without proper licensing, in violation of various States laws that govern car sales; and (iii) as a result of the above, the Company’s financial statements were materially false and misleading at all relevant times.
On March 9, 2015, a complaint was filed in Federal Court against TrueCar alleging that car dealers were injured by the Company’s business practices which violated unfair competition and deceptive trade practice laws. On this news, shares of TrueCar fell $0.47, to close at $16.50, on May 10, 2015.
On May 20, 2015, another lawsuit was filed against TrueCar in Los Angeles County Superior Court, asserting that TrueCar violates various laws that govern car sales in the state of California including claims that TrueCar acts as a dealer and broker in car sales transactions without proper licensing. On the news, shares of TrueCar fell $1.04, or over 6.9%, to close at $13.99 on May 20, 2015.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website www.whafh.com. All e-mail correspondence should make reference to the “TrueCar” Investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: email@example.com, firstname.lastname@example.org or email@example.com Tel: (800) 575-0735 or (212) 545-4774NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...